Suppr超能文献

观察性数据在比较有效性研究中的应用:他汀类药物随机试验与冠心病一级预防的模拟。

Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.

机构信息

Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.

出版信息

Stat Methods Med Res. 2013 Feb;22(1):70-96. doi: 10.1177/0962280211403603. Epub 2011 Oct 19.

Abstract

This article reviews methods for comparative effectiveness research using observational data. The basic idea is using an observational study to emulate a hypothetical randomised trial by comparing initiators versus non-initiators of treatment. After adjustment for measured baseline confounders, one can then conduct the observational analogue of an intention-to-treat analysis. We also explain two approaches to conduct the analogues of per-protocol and as-treated analyses after further adjusting for measured time-varying confounding and selection bias using inverse-probability weighting. As an example, we implemented these methods to estimate the effect of statins for primary prevention of coronary heart disease (CHD) using data from electronic medical records in the UK. Despite strong confounding by indication, our approach detected a potential benefit of statin therapy. The analogue of the intention-to-treat hazard ratio (HR) of CHD was 0.89 (0.73, 1.09) for statin initiators versus non-initiators. The HR of CHD was 0.84 (0.54, 1.30) in the per-protocol analysis and 0.79 (0.41, 1.41) in the as-treated analysis for 2 years of use versus no use. In contrast, a conventional comparison of current users versus never users of statin therapy resulted in a HR of 1.31 (1.04, 1.66). We provide a flexible and annotated SAS program to implement the proposed analyses.

摘要

本文回顾了使用观察性数据进行疗效比较研究的方法。基本思路是通过比较治疗的起始者和非起始者,使用观察性研究来模拟假设的随机试验。在调整了测量的基线混杂因素后,就可以对治疗意向进行观察性模拟分析。我们还解释了两种方法,在进一步调整了测量的时变混杂因素和选择偏倚后,使用逆概率加权法对符合方案和实际治疗分析进行模拟。例如,我们使用英国电子病历中的数据,实施了这些方法来估计他汀类药物在冠心病(CHD)一级预防中的效果。尽管存在强烈的指示性混杂,但我们的方法检测到他汀类药物治疗的潜在益处。他汀类药物起始者与非起始者的 CHD 发生率的意向治疗风险比(HR)为 0.89(0.73,1.09)。在符合方案分析中,CHD 的 HR 为 0.84(0.54,1.30),在实际治疗分析中,使用 2 年与不使用的 HR 为 0.79(0.41,1.41)。相比之下,常规比较当前使用他汀类药物治疗的患者与从未使用过他汀类药物治疗的患者,HR 为 1.31(1.04,1.66)。我们提供了一个灵活且带注释的 SAS 程序来实现所提出的分析。

相似文献

2

引用本文的文献

5
Drug combination-wide association studies of cancer.癌症的药物联合全基因组关联研究。
Commun Med (Lond). 2025 Jul 9;5(1):285. doi: 10.1038/s43856-025-00991-8.

本文引用的文献

2
Statins for the primary prevention of cardiovascular disease.他汀类药物用于心血管疾病的一级预防。
Cochrane Database Syst Rev. 2011 Jan 19(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
8
The hazards of hazard ratios.风险比的危害
Epidemiology. 2010 Jan;21(1):13-5. doi: 10.1097/EDE.0b013e3181c1ea43.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验